Lv76
3859 积分 2020-04-21 加入
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
1小时前
待确认
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise
11小时前
已完结
Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States
21小时前
已完结
A Combination Therapy of Cyclophosphamide and Immunomodulating Agents in Cancer
1天前
已完结
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma
3天前
已完结
Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
7天前
已完结
A Combination Therapy of Cyclophosphamide and Immunomodulating Agents in Cancer
7天前
已完结
Acute graft-versus-host disease
8天前
已完结
Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
9天前
已完结
皖公网安备34019202002308
